Biomerica (BMRA) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica (BMRA) has outperformed Myriad Genetics (MYGN) over the past year, losing 34.4% versus a loss of 45.0%. Over five years, MYGN leads with a -86.8% price change compared with -95.7% for BMRA. Myriad Genetics is the larger company by market cap ($416.6 million vs $8.4 million), about 49.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | MYGN |
|---|---|---|
| Share price | $1.84 | $4.36 |
| Market cap | $8.44M | $416.55M |
| 1-day change | -1.86% | +3.69% |
| YTD return | -25.00% | -31.71% |
| 1-year return | -34.38% | -45.03% |
| 5-year return | -95.74% | -86.77% |
| Forward P/E | 4.71 | — |
| EPS (TTM) | $-1.30 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $8.59 |
| 52-week low | $1.45 | $2.74 |
| Distance from 52-week high | -42.83% | -49.30% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | -10.22% |
| Average volume | 70.88K | 2.04M |
| Shares outstanding | 4.60M | 95.65M |
| Employees | 50 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 49.4 times larger than Biomerica by market value ($416.55M vs $8.44M).
- BMRA has outperformed MYGN by 10.7 percentage points over the past year.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 50 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
BMRA vs MYGN FAQ
Which is bigger, Biomerica or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $416.55M compared with $8.44M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or MYGN?
BMRA returned -34.38% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.